Latest Articles

  • Analysis of Administrative Practices and Residency Training Curricula in Academic Anesthesiology Programs
    David Hepner, A.R. Bader, D. Correll, L.C. Tsen, B.S. Segal and A.M. Bader
    Cleveland Clinic Journal of Medicine February 2009, 76 (2 esuppl 1) e10;
  • Reviewers 2008
    Cleveland Clinic Journal of Medicine February 2009, 76 (2) 136;
  • Surprises and reaffirmations in 2008 clinical trials
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine January 2009, 76 (1) 6; DOI: https://doi.org/10.3949/ccjm.76a.01001

    Clinical trials in 2008 showed us that too much glucose is bad, but trying too hard to lower it may be worse. Low-density lipoprotein cholesterol promotes cardiovascular morbidity, and starts to do so even when the person is apparently healthy.

  • Hepatitis B: A strategy for evaluation and management
    Hesham M. Elgouhari, MD, Tarek I. Abu-Rajab Tamimi, MD and William Carey, MD
    Cleveland Clinic Journal of Medicine January 2009, 76 (1) 19-35; DOI: https://doi.org/10.3949/ccjm.76a.08025

    A single approach to treatment cannot be applied to all patients. Acute, adult-acquired infection rarely requires treatment, whereas treatment for chronic infection should be based on the patient’s clinical situation and test results.

  • Who should receive the shingles vaccine?
    Aparajita Singh, MD, MPH and Kristin Englund, MD
    Cleveland Clinic Journal of Medicine January 2009, 76 (1) 45-48; DOI: https://doi.org/10.3949/ccjm.75a.08046

    The answer: Nearly everyone who is age 60 and older, immunocompetent, and without contraindications to it.

  • JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
    Mehdi H. Shishehbor, DO, MPH and Stanley L. Hazen, MD, PhD
    Cleveland Clinic Journal of Medicine January 2009, 76 (1) 37-44; DOI: https://doi.org/10.3949/ccjm.75a.08105

    How low should we go with low-density lipoprotein cholesterol, and at what cost? What is the role of screening C-reactive protein? The JUPITER study partially answered these questions.

  • Depression and heart disease: What do we know, and where are we headed?
    Leo Pozuelo, MD, Jianping Zhang, MD, PhD, Kathleen Franco, MD, George Tesar, MD, Marc Penn, MD, PhD and Wei Jiang, MD
    Cleveland Clinic Journal of Medicine January 2009, 76 (1) 59-70; DOI: https://doi.org/10.3949/ccjm.75a.08011

    Depression is a risk factor for new cardiac disease and has a detrimental effect in established cardiac disease. Clinicians should routinely screen for it in cardiac patients and should not hesitate to treat it.

  • Alzheimer disease: Time to improve its diagnosis and treatment
    Alzheimer disease: Time to improve its diagnosis and treatment
    Stephen Salloway, MD, MS and Stephen Correia, PhD
    Cleveland Clinic Journal of Medicine January 2009, 76 (1) 49-58; DOI: https://doi.org/10.3949/ccjm.76a.072178

    Basic research is bringing a much-needed infusion of optimism and urgency to the clinical diagnosis and treatment of Alzheimer disease. Some of its risk factors may be modifiable, and although current drugs offer only modest benefit, true disease-modifying drugs are on the horizon.

  • A persistently swollen lip
    Sergio Vañó-Galván, MD, Paula Moreno-Martin, MD, José-María Arrazola, MD and Pedro Jaén, PhD
    Cleveland Clinic Journal of Medicine January 2009, 76 (1) 12-15; DOI: https://doi.org/10.3949/ccjm.76a.08030

    An otherwise healthy man has had asymptomatic swelling of his lower lip for 10 months. What is the cause? What is the treatment?

  • Let’s not retreat (Excerpt: full version at www.ccjm.org)
    Mark Rutkowski, MD
    Cleveland Clinic Journal of Medicine December 2008, 75 (12) 839; DOI: https://doi.org/10.3949/ccjm.75c.12005

Pages